Table 1.
Meningococcal vaccines by geographic location
| Type of vaccine | Serogroup(s) covered | Name | Licensed age group | Routine vaccination |
|---|---|---|---|---|
| Sub-Saharan Africa | ||||
| Monovalent conjugate | A |
PsA-TT (MenAfriVac Conjugate) |
3 months–29 years |
Meningitis vaccine project: 1–29 years Routine vaccination: 9–18 months |
| Australia | ||||
| Protein | B |
MenB-4C (Bexsero) |
≥2 months Registered for use at ≥2 months, but 1st dose can be given as early as 6 weeks |
<2 years (3 doses if initiation at 6 weeks–5 months; 2 doses if initiation at 6–11 or ≥12 months) 15–19 years (2 doses) |
| Monovalent conjugate | C |
MCC-TT (NeisVac-C) |
≥8 weeks | 12 months |
|
MCC-CRM (Meningitec) |
≥6 weeks | 12 months | ||
|
MCC-CRM (Menjugate) |
≥6 weeks | 12 months | ||
|
MCC-TT/Hib-TT (Menitorix (also covers H. influenzae type b)) |
≥6 weeks | 12 months | ||
| Quadrivalent conjugate | A, C, W, Y |
MenACWY-D (Menactra) |
2–55 years* | Not routinely recommended. Recommended in those with increased risk of meningococcal disease |
|
MenACWY-CRM (Menveo) |
11 years | |||
|
ACWY-TT (Nimenrix) |
1–55 years* | Not routinely recommended. Recommended in those with increased risk of meningococcal disease | ||
| Quadrivalent polysaccharide | A, C, W, Y |
MPSV4 (Menomune) |
≥2 years | Not routinely recommended. Can be administered when repeat dosing not anticipated |
| Mencevax ACWY | ≥2 years | Not routinely recommended. Can be administered when repeat dosing not anticipated | ||
|
Canada Note: Provinces/territories may vary in schedule See http://healthycanadians.gc.ca/apps/schedule-calendrier/index-eng.php | ||||
| Protein | B |
MenB-4C (Bexsero) |
2 months–17 years | Not routinely administered. High-risk individuals |
| Monovalent conjugate | C |
MCC-TT (NeisVac-C) |
≥2 months | 12 months, 12 years** |
|
MCC-CRM (Meningitec) |
≥2 months | 12 months, 12 years** | ||
|
MCC-CRM (Menjugate) |
≥2 months | 12 months, 12 years** | ||
| Quadrivalent conjugate | A, C, W, Y |
MenACWY-D (Menactra) |
9 months–55 years* | 12 years** |
|
MenACWY-CRM (Menveo) |
2 months–55 years* | 12 years** | ||
|
ACWY-TT (Nimenrix) |
12 months–55 years* | 12 years** | ||
| Quadrivalent polysaccharide | A, C, W, Y |
MPSV4 (Menomune) |
≥2 years | Not routinely recommended. Can be administered when repeat dosing not anticipated |
| United Kingdom | ||||
| Protein | B |
MenB-4C (Bexsero) |
≥2 months | 2, 4 and 12–13 months |
| Monovalent conjugate | C |
MCC-TT (NeisVac-C) |
≥2 months | 3 months |
|
MCC-CRM (Menjugate) |
≥2 months | 3 months | ||
|
MCC-CRM (Meningitec) |
≥2 months | Not recommended for <12 months as less immunogenic | ||
|
MCC-TT/Hib-TT (Menitorix (Also covers H. influenzae type b)) |
≥2 months–2 years | 12–13 months | ||
| Quadrivalent conjugate | A, C, W, Y |
ACWY-CRM (Menveo) |
≥2 years | 14 years |
|
ACWY-TT (Nimenrix) |
≥12 months | 14 years | ||
| Quadrivalent polysaccharide | A, C, W, Y |
MenACWY (ACWY Vax) |
>2 years | Not part of routine immunization. Only offered for short-term travel protection in older children and adults |
| United States | ||||
| Protein | B |
MenB-4C (Bexsero) |
10–25 years | Not part of routine vaccination, but may be given at 16–18 years |
|
MenB-FHbp (Trumenba) |
10–25 years | Not part of routine vaccination, but may be given at 16–18 years | ||
| Bivalent conjugate | C,Y |
Hib-MenCY-TT (MenHibrix (also covers H. influenzae type b)) |
6 weeks–18 months | Not part of routine vaccination |
| Quadrivalent conjugate | A, C, W, Y |
MenACWY-D (Menactra) |
9 months–55 years* | Single dose at 11–12 years, with booster at 16 years |
|
MenACWY-CRM ( Menveo) |
2 months–55 years* | Single dose at 11–12 years, with booster at 16 years | ||
| Quadrivalent polysaccharide | A, C, W, Y |
MPSV4 (Menomune) |
≥2 years | Not routinely recommended. Can be administered when repeat dosing not anticipated |
* Guidelines suggest these vaccines can be used among >55 year olds with preference for a conjugate vaccine if more than one meningococcal dose is anticipated
** Either monovalent meningococcal C vaccine or quadrivalent meningococcal conjugate vaccine given at 12 years (depending on local epidemiology and programmatic considerations)